This prospective study aimed to investigate the value of evaluating 18F-FDG PET/CT at baseline and 2 weeks after the initiation of treatment for the early prediction of response and survival in patients with advanced lung adenocarcinomas and EGFR mutations receiving first-line EGFR-TKIs. This evidence concerns the gene EGFR and lung adenocarcinoma.